Press Releases

Investors

Press Releases

 
Press Releases
  Date Title and Summary View
Jan 4, 2012
PASADENA, Calif. — January 4, 2012 — Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology and obesity, today announced that the Investigational New Drug Application (IND) for its first obesity drug candidate, AdipotideTM, was accepted by the U.S. Food and Drug Administration allo...
Dec 20, 2011
PASADENA, Calif. — December 20, 2011 — Arrowhead Research Corporation (NASDAQ: ARWRD), a nanomedicine company with development programs in oncology and obesity, today announced financial results for its fiscal 2011 fourth quarter and year ended September 30, 2011. "2011 was a transformational year for Arrowhead,...
Dec 19, 2011
PASADENA, Calif. — December 19, 2011 — Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology and obesity, announced today that it has appointed Michael S. Perry, Hon BSc, DVM, Ph.D., to its board of directors. Dr. Perry brings over 25 years of successful biot...
Dec 15, 2011
PASADENA, Calif., December 15, 2011 — Arrowhead Research Corporation (NASDAQ:ARWR) today announced that it will report its financial results for the fiscal 2011 fourth quarter and year ended September 30, 2011, on Tuesday, December 20, 2011 at 4:30 p.m. Eastern time (1:30 p.m. Pacific time). To participate in the conference c...
Nov 27, 2011
PASADENA, Calif. — November 7, 2011 — Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology, obesity, and regenerative medicine, today announced the publication of a white paper providing an overview of its proprietary dynamic polyconjugate (DPC) technology for safe ...
Nov 23, 2011
PASADENA, Calif. — November 23, 2011 — Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology, obesity, and regenerative medicine, today announced that it has appointed David Lewis, Ph.D., as Vice President, Biology, and David Rozema, Ph.D., as Vice President, Chemist...
Nov 16, 2011
PASADENA, Calif. — November 16, 2011 — Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology, obesity, and regenerative medicine, today announced the implementation of a 1-for-10 reverse stock split of its common stock. Trading on a post-split basis will begin Novem...
Nov 14, 2011
HOUSTON, TX — November 14, 2011 — Leonardo Biosystems, Inc., an emerging drug delivery company, announced today that it has received the second half of a $2.5 million award from the Texas Emerging Technology Fund (TETF). The initial investment tranche was received in April 2010. Leonardo was founded based on the...
Nov 10, 2011
PASADENA, Calif. — November 10, 2011 — Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology, obesity, and regenerative medicine, today announced the publication of data from Ablaris Therapeutics, Inc.'s lead drug candidate, Adipotide™, demonstrating weight los...
Nov 3, 2011
PASADENA, Calif. — November 3, 2011 — Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology, obesity, and regenerative medicine, today announced that it has appointed Brendan P. Rae, Ph.D., J.D., to the position of Chief Business Officer, effective November 1, 2011. ...
Page: FirstPrevious ...
21
NextLast
= add release to Briefcase